JP2009545620A5 - - Google Patents

Download PDF

Info

Publication number
JP2009545620A5
JP2009545620A5 JP2009523051A JP2009523051A JP2009545620A5 JP 2009545620 A5 JP2009545620 A5 JP 2009545620A5 JP 2009523051 A JP2009523051 A JP 2009523051A JP 2009523051 A JP2009523051 A JP 2009523051A JP 2009545620 A5 JP2009545620 A5 JP 2009545620A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutically acceptable
acceptable salt
use according
vla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545620A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075064 external-priority patent/WO2008017025A2/en
Publication of JP2009545620A publication Critical patent/JP2009545620A/ja
Publication of JP2009545620A5 publication Critical patent/JP2009545620A5/ja
Withdrawn legal-status Critical Current

Links

JP2009523051A 2006-08-02 2007-08-02 併用療法 Withdrawn JP2009545620A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83529006P 2006-08-02 2006-08-02
PCT/US2007/075064 WO2008017025A2 (en) 2006-08-02 2007-08-02 Combination therapy

Publications (2)

Publication Number Publication Date
JP2009545620A JP2009545620A (ja) 2009-12-24
JP2009545620A5 true JP2009545620A5 (enExample) 2010-09-09

Family

ID=38997866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523051A Withdrawn JP2009545620A (ja) 2006-08-02 2007-08-02 併用療法

Country Status (12)

Country Link
US (1) US20100003224A1 (enExample)
EP (1) EP2068868A2 (enExample)
JP (1) JP2009545620A (enExample)
CN (1) CN101495115A (enExample)
AR (1) AR063470A1 (enExample)
AU (1) AU2007281090A1 (enExample)
BR (1) BRPI0714799A2 (enExample)
CA (1) CA2659463A1 (enExample)
IL (1) IL196556A0 (enExample)
MX (1) MX2009001272A (enExample)
RU (1) RU2009107030A (enExample)
WO (1) WO2008017025A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
ES2462517T3 (es) 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
US20130323196A1 (en) 2010-09-17 2013-12-05 Antisense Thereapeutics Ltd Method for mobilizing stem and/or progenitor cells
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
KR20200016407A (ko) 2011-05-16 2020-02-14 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
EP2720690A4 (en) * 2011-06-16 2014-12-31 Childrens Medical Center COMBINED CHEMICAL MODIFICATION OF SPHINGOSIN-1-PHOSPHATE (S1P) AND CXCR4 SIGNALING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND TRANSPLANT
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CN107206085B (zh) * 2014-12-12 2022-01-28 联邦科学和工业研究组织 使用α9整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
BR112018070547A2 (pt) * 2016-04-08 2019-02-12 Syros Pharmaceuticals, Inc. agonistas de rara para o tratamento de aml e mds
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
US20190233524A1 (en) * 2017-09-18 2019-08-01 Tcm Biotech International Corp. Therapeutic combination and method for treating cancer
WO2019113375A2 (en) * 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6080398A (en) * 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
UA44901C2 (uk) * 1994-08-19 2002-03-15 Акцо Нобел Н.В. Оптично анізотропний розчин, спосіб його одержання, спосіб виготовлення целюлозних екструдатів, целюлозне волокно, гумовий виріб та шина транспортного засобу
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5968546A (en) * 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
ATE256659T1 (de) * 1998-05-28 2004-01-15 Biogen Inc Ein vla-4-inhibitor: omepupa-v
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP1741428A3 (en) * 1999-08-13 2007-05-09 Biogen Idec MA, Inc. Cell adhesion inhibitors
ATE428706T1 (de) * 1999-12-17 2009-05-15 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
IL154227A0 (en) * 2000-09-15 2003-07-31 Anormed Inc Chemokine receptor binding heterocyclic compounds
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
HUP0302960A3 (en) * 2000-09-15 2007-03-28 Anormed Inc Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
EP2022787B1 (en) * 2000-09-29 2012-11-28 Genzyme Corporation Process for the preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
EP1615633B1 (en) * 2003-04-22 2012-08-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
CA2558389C (en) * 2004-03-15 2013-10-08 Anormed, Inc. Process for the synthesis of a cxcr4 antagonist
CN101094684A (zh) * 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma

Similar Documents

Publication Publication Date Title
JP2009545620A5 (enExample)
JP2010507567A5 (enExample)
RU2009108289A (ru) Комбинированная терапия
RU2009107030A (ru) Комбинированная терапия
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
NZ707377A (en) Combination therapy methods for treating proliferative diseases
JP2016508134A5 (enExample)
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
JP2012526850A5 (enExample)
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
JP2012532624A5 (enExample)
EP4470615A3 (en) Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
Kurnaz et al. Peripheral blood stem cell mobilization failure
Damon et al. Mobilization of hematopoietic stem cells into the peripheral blood
JP2017527551A5 (enExample)
JP2013540734A5 (enExample)
JP2016501208A5 (enExample)
JPWO2020022507A5 (enExample)
US20160113966A1 (en) Composition and methods of culture supernatant of khyg-1 cells
CN115362253A (zh) 利用维奈托克增强t细胞的方法
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2019241641A3 (en) Cancer treatment methods
Tuffaha et al. Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor
JP2014501778A5 (enExample)